Tumor progression is governed not only by genetic changes in cancer cells but also by epigenetic and environmental factors. Chronic infection and subsequent inflammation are critical environmental and epigenetic factors that contribute to tumor progression 1, 2 . Chief examples include gastric cancer and Helicobacter pylori infection; hepatocellular carcinoma and viral hepatitis; colitis-associated cancer; and pancreatic cancer associated with chronic pancreatitis 1 . Similarly, chronic obstructive pulmonary disease, cigarette smoking and exposure to asbestos and silica are associated with lung inflammation and lung carcinoma [3] [4] [5] . Inflammatory cells in the tumor microenvironment, particularly tumor-associated macrophages (TAMs), constitute an important interface between tumor cells and the immune system 6 . The production of proinflammatory cytokines such as tumor necrosis factor (TNF), interleukin 6 (IL-6) and IL-1β by TAMs not only triggers prosurvival signals in tumor cells but also supports their growth and metastasis 6, 7 . However, the molecular mechanisms that regulate inflammation and tumor progression are unclear.
Post-translational modifications mediated by ubiquitin conjugation are a key regulatory mechanism in cells of the immune response 8, 9 . The ubiquitin signal is interpreted on the basis of the number of attached ubiquitin chains and the topology of their linkage. A polyubiquitin chain is formed when one of the seven lysine residues in ubiquitin is linked to the C-terminal glycine of another ubiquitin. Although ubiquitin contains seven lysine residues, linkage generally occurs via either Lys48 (K48) or Lys63 (K63). K48-linked polyubiquitination mainly targets proteins for proteasomal degradation, whereas K63linked polyubiquitination leads to nonproteasomal modifications, such as subcellular localization or protein-protein interactions 8 . The HECT-type E3 ligase Itch is a critical regulator of inflammation 10, 11 . On a mouse C57BL/6 background, Itch deficiency leads to the development of a late-onset lymphoproliferation disorder and chronic pulmonary inflammation 12, 13 . Itch has four Trp-Trp ('WW') domains that recognize the proline-rich Pro-Pro-X-Tyr ('PPXY') consensus sequence (where 'X' is any amino acid) in their substrate targets 14 . Although Itch regulates inflammation, no systematic study has linked Itch to tumorigenesis.
Similar to phosphorylation, protein ubiquitination is reversible, and removal of ubiquitin molecules is mediated by deubiquitinating enzymes such as Cyld 15 . Cyld is encoded by a gene inducible by the transcription factor NF-κB 16 and inhibits NF-κB and the kinase Jnk by removing K63-linked polyubiquitin chains from signaling pathway molecules such as Bcl-3, TRAF2, TRAF6 and NEMO (IKK-γ) [17] [18] [19] [20] [21] . Through its deubiquitinating function, Cyld regulates various human cancers, including lung, hepatocellular, colon and cervical cancers 15 . Cyld also negatively regulates tumor-promoting cytokine secretion by inflammatory cells 22 . Despite such observations, the molecular mechanisms that regulate Cyld function and its role in inflammation remain largely unknown. Here we demonstrate that Itch interacted with Cyld and they acted together to regulate Tak1 and inflammation. lung, liver, spleen and the salivary glands 22 . Cyld deficiency leads to greater susceptibility to spontaneous and chemically induced colitis and colon tumorigenesis 22, 23 . Cyld regulates lung inflammation 24, 25 , and Cyld expression is frequently downregulated in non-small cell lung carcinoma (NSCLC) cell lines 26 . Overexpression of full-length Cyld in NSCLC cell lines results in much less cell growth but overexpression of a catalytically inactive mutant of Cyld does not, which suggests that Cyld acts as tumor suppressor gene for the progression of NSCLC and that its deubiquitinating function is important for this mechanism 26 . To determine the contribution of Itch and Cyld to inflammation and metastasis of lung carcinoma, we inoculated 1 × 10 6 Lewis lung carcinoma (LLC) cells into Cyld −/− , Itch −/− and control C57BL/6 mice intravenously via the tail vein. Both Itch −/− and Cyld −/− mice had a higher mortality rate than that of wild-type mice ( Fig. 1a) . Histological analysis showed aggressive tumor growth in the lungs of Itch −/− and Cyld −/− mice ( Fig. 1b) . Similarly, we observed notable differences between mutant and wild-type mice in tumor multiplicity ( Fig. 1c ) and tumor size ( Fig. 1d) . To investigate the effect of Itch and Cyld deficiency on metastasis, we inoculated mice with LLC cells subcutaneously and analyzed spontaneous lung metastasis. We observed much greater metastasis of LLC tumors in Itch −/− and Cyld −/− mice than in wild-type mice (Supplementary Fig. 1 ). These data suggested that deficiency in Itch or Cyld in the hosts led to more growth and metastasis of lung carcinoma.
Because proinflammatory cytokines secreted by TAMs have been associated with enhanced tumor growth and metastasis 6 , we analyzed cytokine expression by tumor-infiltrated CD11b + cells. We observed higher expression of TNF, IL-6 and IL-1β in both Itch −/− and Cyld −/− cells than in wild-type mice (Fig. 1e) . Similarly, we observed higher expression of these cytokines in whole-tumor nodules isolated from the lungs of Itch −/− and Cyld −/− mice than in those from wild-type mice (data not shown). We observed no significant difference between mutant and wild-type mice in cytokine expression in lung tissues without inoculation with LLC cells (Fig. 1f) , which suggested that Itch and Cyld negatively regulate TAM activity.
Itch interacts with Cyld via the WW-PPXY motifs
Itch regulates TNF-induced NF-κB signaling by modulating turnover of the long variant of the the signaling protein FLIP (cFLIP L ) 27 . The deubiquitinating activity of Cyld interferes with the ubiquitination of TRAF proteins and Tak1, which are involved directly in the TNFassociated NF-κB signaling pathway 15 . As Itch and Cyld can regulate similar pathways, we tested whether these enzymes act together to terminate NF-κB signaling and inflammatory response during tumor growth and metastasis. To determine whether Itch and Cyld can directly interact with each other, we did sequence analysis and found a highly conserved PPXY motif in Cyld ( Fig. 2a) by which Cyld A r t i c l e s could interact with WW domains of Itch. We tested this interaction by transiently transfecting 293T human embryonic kidney cells with Flag-tagged Itch (Flag-Itch) and Myc-tagged Cyld (Myc-Cyld). We immunoprecipitated proteins from cell lysates with control mouse immunoglobulin G (IgG), antibody to Flag (anti-Flag) or anti-Myc. Anti-Myc immunoprecipitated Flag-Itch and vice versa ( Fig. 2b) , which suggested that Itch physically interacted with Cyld. We also generated a fusion protein of glutathione S-transferase (GST) and Itch (GST-Itch) and did a precipitation assay with lysates of 293T cells transfected with Myc-Cyld. GST-Itch precipitated Myc-Cyld, but GST alone did not ( Supplementary Fig. 2) , which confirmed the association. We further tested whether the interaction was direct by using GST-Itch and histidine-tagged Cyld (His-Cyld, expressed in Escherichia coli). GST-Itch precipitated His-Cyld in the precipitation assay ( Fig. 2c) , which confirmed direct interaction between Itch and Cyld.
To determine whether this interaction occurs endogenously in primary cells, we stimulated bone marrow-derived macrophages (BMDMs) with TNF for 30 min, followed by immunoprecipitation with anti-Itch or anti-Cyld. Itch immunoprecipitated together with Cyld ( Fig. 2d ). Itch and Cyld interaction in BMDMs seemed to depend on stimulation, as we did not detect this association in unstimulated cells (data not shown). To test whether the Itch-Cyld interaction occurred via the PPXY motif, we generated a mutant Cyld with substitution of alanine for the tyrosine at position 485 (Cyld(Y485A)) by site-directed mutagenesis. The Y485A substitution disrupted the Itch-Cyld interaction ( Fig. 2e ). Together these data indicated that Itch formed a complex with Cyld via its interaction through PPXY motif.
Itch targets Tak1 for K48-linked ubiquitination
Next we sought to understand the role of the Itch-Cyld complex in the regulation of inflammatory response. Signaling driven by inflammatory stimuli converges at the NF-κB-inhibitor (IκB) kinase (IKK) complex, a trimeric holoenzyme composed of the catalytic subunits IKKα and IKKβ and the regulatory subunit IKKβ (NEMO) 28 . Tak1 is a key intermediate that transmits signals from receptor complexes to IKK. Tak1 associates with TRAF2 or TRAF6 after stimulation with TNF or with Toll-like receptor ligands and IL-1, respectively, to initiate a signaling cascade. Both TRAF2 and TRAF6 are RING domain ubiquitin ligases that catalyze K63-linked polyubiquitin chains, which leads to Tak1 autophosphorylation 29 . Activated Tak1 phosphorylates IKKβ in the activation loop, which leads to the activation of IKK 30 . IKK in turn phosphorylates IκBα, which leads to nuclear translocation of NF-κB and transcription of target genes encoding inflammatory molecules 28 . Tak1 activation is transient and is rapidly inactivated, which is important for the prevention of prolonged inflammatory responses [31] [32] [33] . Cyld cleaves the K63-linked polyubiquitin chain on Tak1 (ref. 23 ). Because Itch deficiency leads to persistent activation of IKK and the kinase Jnk 34 , similar to Cyld deficiency 17-21 , we reasoned that Itch may participate in terminating Tak1 activation by K48-linked polyubiquitination. To test this, we expressed Flag-Tak1 with Myc-Itch together along with hemagglutinin (HA)-tagged wildtype ubiquitin or ubiquitin mutants with substitution of all lysine residues except K48 (Ub(K48)) or K63 (Ub(K63)). We observed slowly migrating high-molecular-mass polyubiquitinated forms of Tak1 when Itch and Tak1 were expressed together with wild-type ubiquitin ( Fig. 3a) . Notably, Itch catalyzed Tak1 polyubiquitination when expressed together with Ub(K48), but not when expressed together with Ub(K63) (Fig. 3a) , which suggested that Itch targets Tak1 for K48-linked ubiquitination but not for K63-linked ubiquitination. To confirm the specificity of Itch as the E3 ligase, we generated an Itch mutant with substitution of alanine for the cysteine residue at position 830 (Itch(C830A)) 35 . Expression of Itch(C830A) with either wild-type ubiquitin or Ub(K48) did not lead to ubiquitination of Tak1 ( Fig. 3a) .
To further confirm that Itch targets Tak1 for K48-linked polyubiquitination, we used a ubiquitin mutant with substitution of arginine for the lysine residue at position 48 (Ub(K48R)). Coexpression of Ub(K48R) and Itch did not polyubiquitinate Tak1 (Fig. 3b ). Next we determine whether another functionally related E3 ligase, Cbl-b 8 , ubiquitinated Tak1. Expression of Cbl-b together with Tak1 did not lead to ubiquitination of Tak1 (Supplementary Fig. 3) , which suggested that Itch is the specific ligase for Tak1.
Itch-Cyld edits Tak1 ubiquitination
Because Cyld cleaves K63-linked ubiquitination of Tak1 (ref. 23) , we hypothesized that the Itch-Cyld complex sequentially cleaves K63linked ubiquitin chain and catalyzes K48-linked ubiquitination to deactivate Tak1 and terminate NF-κB signaling. Expression of TRAF2 together with Tak1 and Ub(K63) led to Tak1 polyubiquitination (Fig. 3c) .
As expected, a RING-deletion mutant of TRAF2 that lacks ligase activity 36 did not ubiquitinate Tak1 (Fig. 3c) . Inclusion of wild-type Cyld led to less ubiquitination of Tak1, but inclusion of a Cyld mutant with substitution of alanine for the cysteine residue at position 601 (Cyld(C601A)), which lacks deubiquitinating activity 37 , did not (Fig. 3c) ; this suggested that Cyld deubiquitinated Tak1. Similarly, Cyld(Y485A) was defective in deubiquitinating Tak1 (Fig. 3c) . Itch did not ubiquitinate Tak1 in the presence of Cyld, TRAF2 and Ub(K63), but with that same combination, the addition of Ub(K48) led to ubiquitination of Tak1 (Fig. 3c) . This suggested that after cleavage of the K63-linked polyubiquitin chain, Itch catalyzed K48-linked polyubiquitination. We ruled out the possibility of cross-reactivity of antibody to the Xpress tag (HX) and anti-Flag in these experiments, as we obtained single specific bands (Supplementary Fig. 4) .
To further confirm these results, we used Ub(K48R) and a ubiquitin mutant with substitution of arginine for the lsine residue at position 63 (Ub(K63R)). Expression of TRAF2 with Ub(K48R) led to polyubiquitination of Tak1 , but expression of TRAF2 with Ub(K63R) did not (Fig. 3d) . As we expected, the TRAF2 RING-deletion mutant 36 was defective in catalyzing the ubiquitin chain on Tak1 (Fig. 3d) . Wild-type Cyld deubiquitinated Tak1, but Cyld(C601A) 37 did not ( Fig. 3d) . Similarly, Cyld(Y485A) was defective in deubiquitination ( Fig. 3d) . Itch did not ubiquitinate Tak1 (Fig. 3d) in the presence of Cyld, TRAF2 and Ub(K48R), but with that same combination, the addition of Ub(K63R) led to ubiquitination of Tak1 (Fig. 3d) . We obtained similar results with TRAF6 ( Supplementary Fig. 5 ).
To further demonstrate that Cyld-mediated cleavage of the Lys63linked ubiquitin chain formed by TRAF2 was a prerequisite for Itchmediated K48-linked ubiquitination, we used Flag-Ub(K63) and HA-Ub(K48). Itch did not form a K48-linked ubiquitin chain on Tak1 without Cyld-mediated removal of the K63-linked ubiquitin chain (Fig. 3e) . These results suggested that Itch and Cyld acted together to 'switch' K63-linked ubiquitination to K48-linked ubiquitination.
We also determined whether additional deubiquitinases, A20 and Cezanne 38, 39 , which deubiquitinate the signaling molecule RIP1, likewise regulated Tak1 ubiquitination. We expressed Tak1, Ub(K63) and TRAF2 together with either A20 or Cezanne. Neither A20 nor Cezanne deubiquitinated Tak1 (Supplementary Fig. 6) , which suggested substrate specificity of Cyld. Next we investigated whether Itch-mediated K48-linked polyubiquitination led to Tak1 degradation. Expression of HA-Tak1 together with increasing amounts of Flag-Itch resulted in lower abundance of Tak1, but expression with Itch(C830A) did not (Fig. 4a) ; this suggested that Itch regulated the turnover of Tak1. Further, the proteasome inhibitor MG132 blocked Itch-mediated degradation of Tak1 in a similar experiment (Fig. 4b) .
This suggested that Itch-mediated K48-linked ubiquitination promoted proteasomal degradation of Tak1. 
A r t i c l e s
We immunoprecipitated proteins from cell lysates with anti-TRAF2 and analyzed the immunoprecipitated by immunoblot with antibody to phosphorylated Tak1 to assess TRAF2-associated activation of Tak1. Tak1 phosphorylation peaked within 5 min after stimulation in wild-type macrophages, and the phosphorylation diminished to baseline within 30 min; however, we observed sustained Tak1 phosphorylation in Itch −/− and Cyld −/− BMDMs (Fig. 5a) . We reprobed the membranes with anti-Tak1 to analyze total TRAF2-associated Tak1. Similar to Tak1 phosphorylation, the association of Tak1 with TRAF2 was transient in wild-type macrophages; however, Itch and Cyld deficiency prolonged the association. To analyze the effect of deficiency in Itch or Cyld on total cellular abundance of Tak1, we analyzed cell lysates by immunoblot with anti-Tak1. We observed only a marginal decrease in total Tak1 protein in wild-type BMDMs stimulated with TNF. This finding suggested that the Itch-Cyld complex degraded the Tak1 associated with TRAF complex but not the entire pool of Tak1 in the cell during an inflammatory response.
Because Tak1 activation is directly linked to the secretion of proinflammatory cytokines, we analyzed the expression of IL-6, TNF and IL-1β in BMDMs after stimulation with TNF. Expression of mRNA encoding proinflammatory cytokines was sustained for 12 h in Itch −/− and Cyld −/− BMDMs (Fig. 5b) . We also analyzed cytokine concentrations in culture supernatants by enzyme-linked immunosorbent assay (ELISA). Itch and Cyld deficiency led to more secretion of proinflammatory cytokines (Fig. 5c) . This indicated that cleavage of K63-linked polyubiquitination was not sufficient to deactivate Tak1 and its downstream effector function and that sequential Itch-mediated K48-linked ubiquitination was essential. Similarly, we observed sustained Tak1 phosphorylation and higher expression of cytokine-encoding mRNA in Itch −/− and Cyld −/− BMDMs stimulated with lipopolysaccharide ( Supplementary Fig. 7) .
To determine whether inhibiting Tak1 activation attenuates cytokine production, we used (5Z)-7-oxozeanol, a selective inhibitor of Tak1 (ref. 40 ). Preincubation of BMDMs for 30 min before TNF stimulation with various concentrations of (5Z)-7-oxozeaenol decreased the abundance cytokine-encoding mRNA in a dose-dependent manner (Fig. 6a) . We obtained similar results for BMDMs stimulated with lipopolysaccharide in the presence of (5Z)-7-oxozeaenol ( Supplementary Fig. 8) . Also, preincubation of BMDMs with (5Z)-7oxozeaenol inhibited the sustained Tak1 phosphorylation in Itch −/− and Cyld −/− BMDMs (Fig. 6b) . Next we determined whether (Fig. 6c,d) . These data collectively suggested that sustained activation of Tak1 in Itch −/− and Cyld −/− BMDMs led to chronic production of proinflammatory cytokines.
Enzyme activity of Itch and Cyld regulates Tak1
To determine the functional relevance of Tak1 regulation by Itch and Cyld, we reconstituted Itch −/− mouse embryonic fibroblasts (MEFs) with wild-type Itch and the ligase-deficient Itch(C830A) mutant. As expected, reconstitution of Itch −/− MEFs with wild-type Itch normalized Tak1 activation, but reconstitution of Itch(C830A) did not (Fig. 7a) . Similarly, IL-6 production by Itch −/− MEFs reconstituted with wildtype Itch was similar to that of wild-type MEFs, but reconstitution with Itch(C830A) did not produce this effect (Fig. 7b) . That result was consistent with the finding that Itch(C830A) did not ubiquitinate Tak1 (Fig. 3a) . We also reconstituted Cyld −/− MEFs with wildtype Cyld, Cyld(C601A) (which lacks deubiquitinating activity 37 ) or Cyld(Y485A) (which does not interact with Itch). Reconstitution of Cyld −/− MEFs with wild-type Cyld restored transient Tak1 activation (Fig. 7c,d) and normalized IL-6 production. However, Cyld(C601A) and Cyld(Y485A) were impaired in the termination of Tak1 activation. Collectively, these data indicated that the deubiquitinating function of Cyld and its interaction with Itch were essential for the termination of Tak1 and the production of inflammatory cytokines.
To further confirm the role of the interaction of Itch and Cyld in terminating Tak1 activation in macrophages, we reconstituted Cyld −/− BMDMs with wild-type Cyld or Cyld(Y485A) (which does not interact with Itch). Expression of wild-type Cyld restored transient Tak1 activation, but expression of Cyld(Y485A) did not (Fig. 8a) . Similarly, wild-type Cyld almost completely reversed the enhanced cytokine production of Cyld −/− BMDMs; however, expression of Cyld(Y485A) had only a minimal effect on this (Fig. 8b,c) . These data suggested that Itch and Cyld acted together to regulate cytokine production by inflammatory cells.
DISCUSSION
In this study, we have demonstrated that Itch formed a ubiquitinediting complex with Cyld via interaction through WW-PPXY motifs. The Itch-Cyld complex promoted the transition of K63linked ubiquitination to K48-linked ubiquitination by sequentially cleaving the K63-linked ubiquitin chain and by catalyzing K48linked ubiquitination on Tak1. During the early phase of inflammatory responses induced by TNF or Toll-like receptors, the E3 ligases TRAF2 and TRAF6 promote K63-linked ubiquitination in the kinase domain 29 , which promotes phosphorylation of Tak1 that leads to IKK-NF-κB activation and the transcription of genes encoding proinflammatory cytokines 42 . We propose that the combined activity of Itch and Cyld shifts Tak1 ubiquitination from K63-linked chains to K48-linked chains, triggering the proteasomal degradation of Tak1 and thus terminating the inflammatory response. We detected the Itch-Cyld association only after stimulation of BMDMs with TNF, which suggested that extracellular signals were required. The molecular mechanisms that regulate formation of the Itch-Cyld complex are unclear. Cyld expression could be upregulated by TNF, and IL-1β, via the IKK-NF-κB pathway 16, 24, 25 , could trigger the association of Cyld with Itch. Alternatively, the Itch-Cyld association could be regulated by mechanisms mediated by NF-κB-dependent phosphorylation. Such a phenomenon has recently been demonstrated for the recruitment of Itch to the A20 complex by the binding protein TAXIBP1 (refs. 34, 43) .
The molecular basis for the chronic multiorgan inflammatory disorder of Itch −/− mice has been attributed to biased T helper type 2 differentiation owing to a defect in the degradation of the Itch target JunB 13 . Itch also regulates T cell tolerance, as Itch −/− T cells are resistant to anergy induction 44 and TGF-β-mediated suppression 11 . Our results here have indicated a critical role for Itch in the regulation of cells of the innate immune system via targeting Tak1 for proteasomal degradation. Our findings and other published reports that Itch is a component of the A20, TAXIBP1 and RNF11 complex 34, 43 raise the possibility that Itch has a more prominent role as a negative regulator of inflammatory signaling in cells of the innate immune response.
Itch seems to be a specific ligase that targets Tak1 for K48-linked ubiquitination, because Cbl-b, a functionally related E3 ligase 8 that also regulates the NF-κB pathway 45 , did not ubiquitinate Tak1. Similarly, several other deubiquitinating enzymes, including A20, Cezanne, USP4 and USP21, negatively regulate the NF-κB pathway 39 . In our assay system, we did not detect deubiquitinating activity of A20 or Cezanne toward Tak1, which suggests specificity of Cyld. However, we have not completely ruled out the possibility of the involvement of A r t i c l e s additional deubiquitinating enzymes or E3 ligases in the regulation of Tak1 and downstream signaling. We also observed that Itch −/− and Cyld −/− TAMs produced more tumor-promoting inflammatory cytokines. Consistent with that, Itch −/− and Cyld −/− mice showed aggressive growth and metastasis of transplanted LLC tumors. However, it is not clear whether the enhanced tumor growth we observed was due exclusively to the chronic production of tumor-promoting cytokines by TAMs. Aberrant T cell responses in Itch −/− and Cyld −/− mice 8, 10, 11, 13 may also contribute to tumor growth. Further analysis is essential for understanding of these mechanisms that could lead to therapeutic targeting.
Consistent with our findings, cytokines produced by activated cells of the innate immune response, particularly TAMs, are associated with inflammation and cancer 6 . In clinical studies, large numbers of TAMs are correlated with angiogenesis, metastasis and poor prognosis 6 . The tumor-promoting role of TAMs is linked to NF-κB-mediated production of proinflammatory cytokines, including TNF and IL-6 (ref. 7) , which supports the idea that excessive, chronically produced proinflammatory cytokines contribute to tumor progression. We have identified a coordination between Itch and Cyld that restricted prolonged inflammatory signaling and secretion of tumor-promoting inflammatory cytokines by macrophages.
Our studies also showed that the Tak1-selective inhibitor (5Z)-7-oxozeaenol inhibited tumor-promoting cytokine production by BMDMs. As NF-κB has emerged as a key internal factor that promotes inflammation and cancer 1,2 , several approaches have been designed to block NF-κB, including inhibitors of IKK and proteasome inhibitors to inhibit degradation of IκB 46 . Although proteasome inhibitors such as bortezomib block NF-κB in a variety of cells and are being used in clinical trials to treat multiple myeloma, the results of phase 1 or phase 2 clinical trials have indicated that the drug has limited activity in the treatment of advanced NSCLC 47, 48 . In addition, complications have been reported after global inhibition of NF-κB through genetic and pharmacological approaches 49 . That indicates that more specific inhibitors are needed to dampen inflammation and tumor progression. Our results have provided mechanistic insight into the regulation of Tak1 for the termination of inflammatory cytokine production, which can be exploited therapeutically to target inflammatory cells in the tumor microenvironment. Through the targeting of inflammatory cells, which are more genetically normal and stable than genetically unstable carcinoma cells, the development of drug resistance could be minimized. In addition, combining conventional cytotoxic cancer therapy with inhibitors that block inflammatory responses could potentially enhance current therapeutic strategies.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
Note: Supplementary information is available on the Nature Immunology website.
